3933.HK Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 10:08):

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products...

Stats
Tagesvolumen	2.85M
Durchschnittsvolumen	3.96M
Marktkapitalisierung	16.77B
EPS	HKD0 ( 2024-03-26 )
Last Dividend	HKD0.131 ( 2023-09-14 )
Next Dividend	HKD0 ( N/A )
P/E	5.73
ATR14	HKD0.00700 (0.08%)

Volumen Korrelation

Lang: 0.04 (neutral)

Kurz: -0.25 (neutral)

Signal:(42.349) Neutral

United Laboratories Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

United Laboratories Korrelation - Währung/Rohstoff

-0.36
( neutral )

-0.17
( neutral )

0.00
( neutral )

-0.18
( neutral )

0.29
( neutral )

United Laboratories Finanzdaten

Annual	2023
Umsatz:	HKD13.74B
Bruttogewinn:	HKD6.33B (46.11 %)
EPS:	HKD1.490

FY	2023
Umsatz:	HKD13.74B
Bruttogewinn:	HKD6.33B (46.11 %)
EPS:	HKD1.490

FY	2022
Umsatz:	HKD11.33B
Bruttogewinn:	HKD4.97B (43.84 %)
EPS:	HKD0.870

FY	2021
Umsatz:	HKD9.70B
Bruttogewinn:	HKD4.21B (43.40 %)
EPS:	HKD0.560

Financial Reports:

No articles found.

United Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0801 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.196 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

United Laboratories Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.42 - Stable (11.58%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.156	2008-05-26
Last Dividend	HKD0.131	2023-09-14
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	15	--
Total Paid Out	HKD1.398	--
Avg. Dividend % Per Year	0.00%	--
Score	2.65	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.42
Div. Directional Score	7.66	--

Next Divdend (Est)
(2024-11-19)

HKD0.150 Estimate 2.95 %

Dividend Stability

0.24 Very Poor

Dividend Score

2.65

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2230.HK	Ex Dividend Knight	2023-09-21	Semi-Annually	0.00%
1243.HK	Ex Dividend Junior	2023-08-25	Annually	0.00%
0308.HK	Ex Dividend Junior	2023-09-18	Annually	0.00%
3993.HK	Ex Dividend Junior	2023-06-29	Annually	0.00%
1800.HK	Ex Dividend Junior	2023-06-20	Annually	0.00%
0836.HK	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
0002.HK	Ex Dividend Knight	2023-09-04	Quarterly	0.00%
2382.HK	Ex Dividend Junior	2023-05-30	Annually	0.00%
1373.HK	Ex Dividend Knight	2023-10-04	Semi-Annually	0.00%
0435.HK	Ex Dividend Knight	2023-09-21	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.197	1.500	6.07	9.10	[0 - 0.5]
returnOnAssetsTTM	0.129	1.200	5.72	6.86	[0 - 0.3]
returnOnEquityTTM	0.223	1.500	8.64	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.08	0.800	4.60	3.68	[1 - 3]
quickRatioTTM	1.528	0.800	5.72	4.57	[0.8 - 2.5]
cashRatioTTM	0.643	1.500	7.54	10.00	[0.2 - 2]
debtRatioTTM	0.0714	-1.500	8.81	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.659	2.00	9.78	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.400	2.00	9.80	10.00	[0 - 20]
debtEquityRatioTTM	0.118	-1.500	9.53	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.461	1.000	5.65	5.65	[0.2 - 0.8]
operatingProfitMarginTTM	0.231	1.000	7.38	7.38	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.798	1.000	6.68	6.68	[0.2 - 2]
assetTurnoverTTM	0.654	0.800	8.98	7.18	[0.5 - 2]
Total Score				10.90

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.63	1.000	9.53	0	[1 - 100]
returnOnEquityTTM	0.223	2.50	9.12	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.400	2.00	9.87	10.00	[0 - 30]
dividendYielPercentageTTM	2.35	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.659	2.00	9.78	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0872	1.000	-0.321	0	[0.1 - 0.5]
Total Score				4.42

United Laboratories

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.